Roche Holding has one of the most promising treatments for Alzheimer’s in clinical trials. The drug is several years away ...

The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...

Roche explains exactly how he harnessed the science of heat training to deliver his unlikely time at the scorching 100-mile ...

Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate disappointed in phase 2, disclosed (PDF) the setback as part of a wider ...

Roche's activity in this area is represented by RG6279, an anti-PD-1 antibody fused to an engineered, variant form of IL-2, which is in phase 1 clinical testing.

New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets to be detected simultaneously in a single patient sample on the high throughput molecular diagnostic ...

Roche Holding saw its EPS decline at a compound rate of 6.7% per year, over the last three years. This reduction in EPS is ...

The family that started the Roche Bros. supermarket chain over 70 years ago is selling a controlling interest in the local ...

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging ...

CEO of Roche Pharmaceuticals, said during a press conference Wednesday. In the third quarter, Vabysmo’s sales grew by 56% year over year to surpass 1 billion Swiss francs ($1.2 billion).

Basel, 05 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts ...

Roche put forward new data on two of its upcoming, non-invasive blood tests designed to help rule out a diagnosis of ...